Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)

NCT04850638 | Completed Phase 1

• 1 other identifier: SHR4640-108
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to evaluate the effect of SHR4640 tablets on the pharmacokinetics of furosemide tablets in healthy male volunteers, using a single-center, single-arm, open, self-control design.

Conditions

Healthy Male Subjects

Outcome Measures

Primary Outcomes (5)

• Cmax

  Peak plasma concentration

  Day1 to Day10

• AUC0-t

  Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.

  Day1 to Day10

• AUC0-inf (if available)

  Area under the curve from time 0 to infinity

  Day1 to Day10

• Ae

  Cumulative Amount of excretion

  Day1 to Day10

• CLr

  Renal Clearance

  Day1 to Day10

Secondary Outcomes (4)

• t1/2

  Day1 to Day10

• Tmax

  Day1 to Day10

• CL/F

  Day1 to Day10

• Vz/F

  Day1 to Day10

Study Arms (1)

SHR4640 tablets

EXPERIMENTAL

Drug: SHR4640 tablets and furosemide tablets

Interventions

SHR4640 tablets and furosemide tablets DRUG

SHR4640 tablets and furosemide tablets

SHR4640 tablets

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial;
• Adult males aged between 18 and 45 (including both ends, whichever is the time of signing the informed consent form);
• Body weight ≥ 50kg and body mass index (BMI): 19\~26kg/m2 (including both ends).

You may not qualify if:

• Have a fertility plan or refuse to use medically approved contraceptives within 1 month from the screening period to the last medication;
• Smokers (those who smoke more than 5 cigarettes per day on average);
• During the first month of screening, the average daily alcohol intake was more than 25g (for example, 750mL beer, 250mL wine, or 50mL liquor) or those who were positive for alcohol in blood test or alcohol breath test during screening;
• Those who have eaten grapefruit or its fruit juice products, any caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.), alcoholic food or beverages within 2 days before administration;
• Drug abusers or those who were positive in urine drug test during screening;
• The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance
• Any clinical history of serious illness or any disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous system, digestive, urinary or blood, immune, mental and metabolic diseases;
• Allergic constitution, or allergic to any ingredient in SHR4640 and furosemide tablets, or allergic to sulfonamides or thiazide diuretics, or allergic to any food ingredient, or having special dietary requirements, unable to follow a uniform diet;
• Previous history of urinary diseases (such as benign prostatic hyperplasia, urinary tract stenosis) or other diseases that lead to dysuria;
• Screen those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
• Those who donated blood (or lost blood) and donated blood (or lost blood) ≥ 400 mL within 3 months before screening, or received blood transfusion;
• During screening, physical examination, vital signs, laboratory examination (whole blood cell analysis, blood biochemical analysis, blood electrolyte examination, urine analysis, fasting blood lipids, thyroid function), 12-lead ECG, X-chest X-ray and abdominal B-ultrasound were abnormal and had clinical significance.
• When screening, systolic blood pressure was less than 90mmHg or greater than 140mmHg, and / or diastolic blood pressure was less than 60mmHg or greater than 90mmHg;
• Urinary system ultrasound suggested or suspected urinary system crystals or stones during screening;
• Those whose serum uric acid was higher than 420 μ mol / L or had a previous history of hyperuricemia and / or gout;

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Interventions

ruzinurad; Furosemide

Intervention Hierarchy (Ancestors)

Sulfanilamides; Sulfonamides; Amides; Organic Chemicals; Aniline Compounds; Amines; Sulfones; Sulfur Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 19, 2021
• First Posted: April 20, 2021
• Study Start: June 28, 2021
• Primary Completion: September 5, 2021
• Study Completion: September 14, 2021
• Last Updated: July 11, 2022

Record last verified: 2022-07

Locations

CN (1)